title: Molecular targets for the treatment of fibrosing cholangiopathies.
abstract: Emerging pathophysiologic insights are leading to novel approaches to treating fibrosing cholangiopathies. The current treatment, using ursodeoxycholic acid (UDCA), may slow the progression of some chronic cholangiopathies but cannot heal them. Apart from immunosuppressive interventions aimed at minimizing immune-mediated damage, the use of specific modifiers of hepatobiliary secretory and cytoprotective mechanisms may eventually give rise to a new class of disease-modifying anti-cholangiofibrotic drugs.
authors: Department of Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors: L J
authors: LJ
authors: Maillette de Buy Wenniger
authors: R P
authors: RP
authors: Oude Elferink
authors: U
authors: U
authors: Beuers
mesh_terms: D001659:Biliary Tract / Q000166:cytology / Q000187:drug effects / Q000503:physiopathology; D015209:Cholangitis, Sclerosing / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002779:Cholestasis / Q000188:drug therapy / Q000503:physiopathology; D022781:Hepatocytes / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects / Q000502:physiology; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D018160:Receptors, Cytoplasmic and Nuclear; D014580:Ursodeoxycholic Acid